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Abstract: The incidence of multiple meningiomas (MMs) without stigmata of 
neurofibromatosis or family history of meningiomatosis is rare. MMs with atypical 
histology are even rarer, since most of them have benign histology. The authors report 
three cases of MMs, of which the symptomatic meningioma removed was an atypical 
meningioma (AM). We also review their possible pathogenesis and histopathology. 
Although there has not been established any MMs management and therapy strategy so 
far, our recommendation is to treat symptomatic and accessible lesions or growing 
tumours and also to prefer a conservative approach consisting of the imaging follow-up 
of asymptomatic lesions. 
Key words: atypical meningioma, multiple meningiomas, meningiomatosis, WHO 
grade II meningiomas 
 
Introduction 
The first description of a multiple 
intracranial meningiomas dates back to 1889 
and was made by Anfimov and Blumenau, 
who had found one large and four small 
tumours on an autopsy that they performed 
(1). Later on, in 1938, Harvey Cushing and 
Louise Eisenhardt explained the pathology of 
this entity and used the term “multiple 
meningiomas” to refer to the case of a patient 
who had “more than one meningioma and less 
than a diffusion of them” (7). 
Meningiomas represent about one third of 
all primary brain tumours in adults (8, 11), 
with an incidence that has increased in recent 
years (10, 35). Majority of meningiomas are 
solitary (33), and MMs are defined as the 
presence of ≥ 2 spatially separated 
metachronous or synchronous meningiomas 
and represents up to 10% of all meningiomas 
(18, 20). They may be sporadic, radiation 
induced or familial, when they occur as type 2 
neurofibromatosis or familial 
meningiomatosis (33). 
Nowadays, the term MMs is used to 
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describe a condition in which a patient has the 
simultaneous or sequential appearance of two 
or more independent meningiomas, whether 
the tumours have the same pathologic 
subtypes or not (13). Nonetheless, Borovich et 
al. considers that MMs might be truly multiple 
when tumours from the same patient have 
different histological subtypes and 
multicentric when tumours have the same 
histology (3). 
The pathophysiologic mechanisms 
underlying the occurrence of MMs have not 
yet been fully understood and thus two 
different hypotheses have been suggested so 
far (16, 34, 37). According to the first theory, 
multiple lesions originate from multicentric 
neoplastic foci and grow independently under 
the stimulation of a supposed tumour-
producing factor. The second theory argues 
that a signal transforming event occurs and an 
original clone of neoplastic meningothelial 
cells spreads throughout the meninges or 
along the cerebrospinal fluid, leading to the 
formation of multiple clonally tumours (13, 
16, 34, 37). Nevertheless, the tumour histology 
and dynamics of histopathological changes 
undergone by these multiple lesions in time 
have not been fully understood. 
MMs also give rise to special treatment 
problems, the most important of which are as 
follows: which lesion is symptomatic, which 
lesion needs to be treated and what is the best 
therapeutic approach, what is the best 
treatment option and how should incidental 
MMs be managed? Due to these aspects, and 
also to their relative rarity, unclear aetiology 
and issues related to management strategy 
(29), MMs have raised the specialists' interest 
and they should constitute a priority in 
meningiomas treatment. 
Methods 
We followed the 3 years evolution of three 
patients with MMs who underwent surgery in 
the “Profesor Dr. Nicolae Oblu” Emergency 
Clinical Hospital of Iasi in 2010, 2012 and 
2013, respectively. The inclusion criteria were 
adult patients (>18 years) with diagnosis of ≥ 2 
separate meningiomas on MRI examination, 
one of which removed by surgery and 
diagnosed with AM (WHO grade II). The 
exclusion criteria were patients with type 2 
neurofibromatosis, history of radiotherapy or 
familial types. 
Results 
The 3 cases of MMs with AM are shown in 
Table 1. 
Case 1. A 64-year-old male patient has had 
slowly progressing vision disorders for about 2 
years, which were examined by several 
ophthalmologists. He had decreased visual 
acuity in both eyes. The MRI examination 
reveals three MMs: one diaphragm sellae 
meningioma with a right parietal meningioma 
and a left parietal meningioma (Figure 1). 
Through a left fronto-temporal approach the 
meningioma of the diaphragm sellae was 
completely resected with good optic chiasma 
and pituitary stalk decompression (Figure 1). 
Postoperative ophthalmologic exam reveald 
that visual acuity of right eye was 6/6 and left 
eye - 1/500 BCVA. Also, the fundus 
examination revealed normally coloured and 
regular edges of the optic disc, C/D ratio 0.3 
for right eye and 0.4 for left eye. 
Case 2. A 65-year-old female patient is 
hospitalized for intracranial hypertension 
syndrome with cerebellar syndrome. The MRI 
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scan reveals the presence of a left transverse 
sinus meningioma (Figure 2. A) with an 
associated left parasagittal meningioma 
(Figure 3). The left transverse sinus 
meningioma was resected through a 
paramedian suboccipital approach (Figure 2. 
B.). Total 0.9 Gy irradiation is also performed, 
both for the remaining tumour on the left 
transverse sinus and for the left frontal 
parasagittal meningioma. 
Case 3. A 73-year-old female patient was 
admitted for gait disorders that have set in 2 
years before and have progressively worsened 
and for 1-month-old intracranial 
hypertension syndrome. The MRI scan reveals 
superior sagittal sinus meningiomatosis. The 
surgical procedure, performed through a 
parieto-occipital approach, consists of 
intracapsular tumour resection and partial 
sinus and infiltrated falx cerebri resection 
(Figure 4). 
In all three patients, both the meningiomas 
resected and the other meningiomas were 
followed by yearly MRI scan. The follow-up 
revealed that, 3 years later, the MMs had not 
increased in size. As concerns AM recurrence, 
a 0.1 cm increase of left transverse sinus 
meningioma was noted in case 2 after one year.
 
TABLE I 
Clinical data of patients with multiple meningiomas, of which one was atypical meningioma 
 Case 1 Case 2 Case 3 
Location 
(AM) 
diaphragm sellae 
meningioma 
left transverse sinus 
meningioma  
parieto-occipital meningioma 
Location of the 
other 
meningiomas 
right parietal 
left parietal 
left parasagittal superior sagittal sinus 
meningiomatosis 
Age, sex M, 64 years F, 65 years F, 73 years 
Symptoms visual acuity 
decreased visual 
acuity in both eyes 
intracranial hypertension 
syndrome, cerebellar 
syndrome 
spastic paraparesis, intracranial 
hypertension syndrome 
Ki - 67 4% 4.7%, with 7.59% on a field 6% 
 
Discussion 
Demography. As concerns the patients' 
demographic data, our findings are in 
accordance with other research shown in 
literature, which proves that the mean age of 
presentation with MMs is the 6th decade of life 
and it is the same as for patients with solitary 
meningioma (12, 13, 26, 27, 33). 
MMs occur much more frequently in 
females than in males, and their predilection 
for the female gender is considerably higher 
than for the male gender, studies showing a 
significantly higher F: M ratio of 3.5:1 in MMs 
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(12, 13, 27). However, it is still unclear why 
female preponderance is much higher in MMs 
than in solitary meningiomas, yet according to 
a recent hypothesis, hormonal dependency 
may be higher, which may be accounted for by 
the stronger progesterone expression in these 
tumours compared with their solitary 
counterparts (13, 32, 33). Moreover, 
Tsermoulas et al. argue that genetic factors 
may enhance the potential for tumorigenesis 
in women (33). Our case series also exhibited 
a female predilection, as two of the three 
patients were women. 
 
 
Figure 1 - (Case 1) Preoperative (A) and postoperative (B) sagittal T1-weighted images with contrast. Multiple 
meningiomas with one right parietal meningioma (C) and one left parietal meningioma (E) 
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Figure 2 - (Case 2) Preoperative (A) and postoperative (B) axial T1-weighted images with contrast of a left 
transverse sinus meningioma 
 
Figure 3 - (Case 2) Axial T1-weighted images with contrast showing a left parasagittal meningioma. No increase 
in size of meningioma was observed at 3 years of follow-up 
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Figure 4 - (Case 3) T1-weighted images with contrast showing a superior sagittal sinus meningiomatosis 
 
 
Figure 5 - (Case 2) T1-weighted images with contrast showing local recurrence of a left transverse sinus 
meningioma at 2 years follow-up 
 
Symptomatology 
The frequency of symptoms in MMs was 
proportional to the size of the tumours, the 
largest meningiomas being more 
asymptomatic, which was to be expected, since 
the mode of presentation of meningiomas is 
due to their mass effect. Skull base and midline 
meningiomas are more symptomatic than 
convexity meningiomas (33), and the most 
common location for meningiomas in 
asymptomatic patients has proven to be the 
convexity (22). In our case series, the 
symptoms were due to the mass effect on optic 
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chiasm and optic nerves (case 1), cerebellum 
(case 2) and motor cortex (case 3). 
MMs distribution in the intracranial space. 
According to the literature, in MMs most 
patients have a major meningioma 
accompanied by one or several smaller 
meningiomas (12, 13), which was also true for 
two of our patients: the two large skull base 
meningiomas (the diaphragm sellae 
meningioma and the transverse sinus 
meningioma) were accompanied by convexity 
meningiomas (Figure 1. C and  E) and 
parasagittal meningiomas (Figure 3). As 
concerns this association, in a study that 
included 39 patients with MMs, Huang et al. 
noted that in MMs a major meningioma is 
often accompanied by one or more smaller 
meningiomas (13). This was also reported by 
Domenicucci et al. that found that 11 of the 14 
cases of MMs were composed of small and 
large meningiomas (12). Thus, Huang et al. 
argue that several different-sized tumours in 
the same MMs case would be an indication of 
the fact that meningiomas may develop at 
different times and that it is possible that an 
original major meningioma may disseminate 
to form multiple foci through the 
subarachnoid or subdural space (13). 
In the same study, they noted that the main 
location of MMs is the cerebral convexity (12, 
13). Huang et al. think that this predilection 
may be accounted for by the assumption that 
MMs develop from the major meningioma 
through the subarachnoid space, since 
disseminated meningioma cell tend to grow at 
the cerebral convexity by the circulation of the 
cerebrospinal fluid (13). This theory is also 
supported by the location of most of the MMs 
in the hemicranial space in some studies (4, 34). 
Histopathology. In MMs, most 
meningiomas are benign (WHO grade I) and 
have uniform histology, the atypical or 
anaplastic subtypes being rare (15). 
Nevertheless, most meningiomas are benign 
on presentation. Thus, Turgot et al. removed 
28 meningiomas from 8 patients, of which 14 
were meningothelial (50%) (34). The 
predominance of the meningothelial subtype 
is also supported by Domenicucci et al.'s 
patient series (12). Other authors also reported 
predominantly benign histologies, yet 
different, like the fibrous and transitional 
subtypes (21) or the psammomatous type (27). 
As concerns meningioma histology in the 
same patient, some studies have shown that 
the same patient may have meningiomas of 
different grade and different histological 
features (13, 19, 21). In a study that they 
recently published in 2017, Tsermoulas et al. 
also found that among patients who had more 
than 2 meningiomas removed, about 1 in 5 had 
tumours of different grades and most of them 
had different histological subtypes. From this 
point of view, some authors argue that these 
findings are evidence of the different origins of 
tumours from multiple foci and that their 
multiplicity is not the consequence of cell 
migration through the subarachnoid space (4, 
19, 21). On the other hand, other authors have 
supported the theory of clonal spread from a 
single tumour (13, 16, 17, 24, 27, 30, 37). Some 
authors are of the opinion that both theories 
may apply in different cases and that further 
research on the genetics of MMs would clarify 
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the controversial standpoints on the histology 
and pathogenesis of these lesions (33). 
Atypical meningiomas. As we have said 
before, most of the published series concluded 
that the vast majority of MMs cases described 
in literature have benign histology (27, 34), the 
atypical or anaplastic subtypes being rare (15). 
As far as the simultaneous occurrence of 
benign and atypical histological grades in 
sporadic MMs is concerned, Mocker et al. 
consider that this is extremely rare (19), as 
literature contains only few reports of benign 
histological types mixed with atypical types (4, 
19, 23, 31).  
Tumour recurrence is one of the main 
problems that have to be dealt with in AM 
management (8). Thus, Huang et al. found 
that four meningiomas in three patients were 
AM and all of these three patients had 
recurrence after the operation (13). In our 
three-patient series, only one AM exhibited 
tumour recurrence after 2 years (case 2). As 
concerns the other meningiomas, on which no 
surgery was performed, they did not grow in 
size during our 3 year follow-up (Figures 1 and 
3). Our findings are in line with Wong et al., 
who did not note the tumour growth rates in 
patients with MMs to be higher than the 
growth rates of incidentally found solitary 
meningiomas (36). 
Genetics of meningiomas. The most 
significant genetic abnormality in sporadic 
solitary meningiomas is the loss of 
heterozygosity on chromosome 22, which 
occurs in about 50% of patients. An early event 
of tumorigenesis in one third of these cases 
was found to be the somatic mutation of the 
NF2 gene (22q12.2) (5). On the other hand, 
familial MMs do not show mutation or loss of 
NF2 (28). 
Some authors have described genetic 
alterations associated with meningioma 
progression and initiation, yet it is not yet 
possible to predict the rate of tumour growth 
or the probability of tumour recurrence (6). 
Thus, the genetics of tumour nodules for the 
appearance of MMs not yet fully known (19). 
Management. Not all patients with MMs 
require treatment, and a challenge in the 
management of MMs may be the 
identification of the responsible tumour. In 
this algorithm, surgical removal remains the 
main form of treatment. Since the neurological 
deficits are usually caused by major tumours 
and peritumoral oedema, the size of the 
meningioma is an important factor in 
determining which of the meningiomas need 
to be removed (9, 13). 
Radiosurgery seems to be an attractive and 
interesting option for MMs up to 3 cm in 
diameter or residual tumours, but further 
research is required to establish its 
effectiveness and determine whether it is safe 
or not (33). Therefore, the authors' opinions 
are controversial: some of them support the 
treatment of asymptomatic meningiomas with 
prophylactic radiosurgery, even without 
documented growth (14, 25), whereas others 
are more reserved on that point and they 
report a complication rate of radiosurgery of 
10% (26). As far as MMs prognosis is 
concerned, it depends on the grade of the 
tumour, on the histological types and on the 
resection degree of the tumour (2, 8). 
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Conclusions 
There has not been established any MMs 
management and therapy strategy so far. Our 
recommendation is to treat the symptomatic 
or the potentially symptomatic tumours and to 
avoid useless procedures and complications. 
The form of treatment is surgical removal, but 
radiotherapy may also be considered and may 
also play an important role, especially for AM. 
Nevertheless, even in MMs only some of the 
lesions require treatment, since most of them 
are small and asymptomatic and they only 
require clinical and imaging follow-up. Our 
philosophy is to treat symptomatic and 
accessible lesions or growing tumours and to 
apply the conservative approach, consisting of 
imaging follow-up for the asymptomatic 
lesions. 
 
Correspondence 
Claudia Florida Costea 
“Prof. Dr. N. Oblu” Emergency Clinical Hospital, 
Iasi, Romania 
E-mail: costea10@yahoo.com 
References 
1.Anfimow J, Blumenau L. Ein fall multipler geschwülste 
in der Schadel¬höle. Neurol Zetralbl. 1889; 8:585. 
2.Black PM. Meningiomas. Neurosurgery. 1993; 32:643-
657. 
3.Borovich B, Doron Y. Recurrence of intracranial 
meningiomas: the role played by regional multicentricity. 
J Neurosurg. 1986; 64(1):58-63. 
4.Butti G, Assietti R, Casalone R, et al. Multiple 
meningiomas: A clinical, surgical, and cytogenetic 
analysis. Surg Neurol. 1989; 31:255-260. 
5.Campbell BA, Jhamb A, Maguire JA, et al. 
Meningiomas in 2009: controversies and future 
challenges. Am J Clin Oncol. 2009; 32(1):73-85.  
6.Carvalho LH, Smirnov I, Baia GS, et al. Molecular 
signatures define two main classes of meningiomas. Mol 
Cancer. 2007; 6:64. 
7.Cushing H, Eisenhardt L. Meningiomas: Their 
Classification, Regional Behavior, Life History, and 
Surgical End Results. C. Thomas, Springfield III, 1938. 
8.Cucu AI, Costea CF, Poeata I, et al. Prognostic factors 
in atypical meningioma. Rom Neurosurg. 2017; 31 
(2):165-171. 
9.Cucu AI, Turliuc MD, Carauleanu A, et al. Chemical 
aspects of peritumoral cerebral edema in atypical 
meningiomas. Rev Chim (Bucharest). 2018; 69:2804-
2807. 
10.Cucu AI, Costea CF, Carauleanu et al. Meningiomas 
related to the Chernobyl irradiation disaster in North-
Eastern Romania between 1990-2015. Rev Chim 
(Bucharest). 2018; 69:1562-1565. 
11.Dolecek TA, Propp JM, Stroup NE, Kruchko C. 
CBTRUS statistical report: primary brain and central 
nervous system tumors diagnosed in the United States in 
2005–2009. Neuro Oncol. 2012; 14(5): 1-49. 
12.Domenicucci M, Santoro A, D’Osvaldo DH, et al. 
Multiple intracranial meningiomas. J Neurosurg. 1989; 
70:41-44. 
13.Huang H, Buhl R, Hugo HH, et al. Clinical and 
histological features of multiple meningiomas compared 
with solitary meningiomas. Neurol Res. 2005; 27:324-332. 
14.Iwai Y, Yamanaka K, Morikawa T, et al. The treatment 
for asymptomatic meningiomas in the era of 
radiosurgery. No Shinkei Geka. 2003; 31:891-897. 
15.Koh YC, Yoo H, Whang GC, et al. Multiple 
meningiomas of different pathological features: case 
report. J Clin Neurosci. 2001; 1(8 Suppl.):40-43. 
16.Larson JJ, Tew JM Jr, Simon M, et al. Evidence for 
clonal spread in the development of multiple 
meningiomas. J Neurosurg. 1995; 83:705-709. 
17.Lomas J, Bello MJ, Alonso ME, et al. Loss of 
chromosome 22 and absence of NF2 gene mutation in a 
case of multiple meningiomas. Hum Pathol. 2002; 33:375-
378. 
18.Lusins JO, Nakagawa H. Multiple meningiomas 
evaluated by computed tomography. Neurosurgery. 1981; 
9:137-141. 
19.Mocker K, Holland H, Ahnert P, et al. Multiple 
meningioma with different grades of malignancy: case 
report with genetic analysis applying single-nucleotide 
polymorphism array and classical cytogenetics. Pathol 
Res Pract. 2011; 207:67-72. 
20.Nahser HC, Grote W, Löhr E, et al. Multiple 
meningiomas. Clinical and computer tomographic 
observations. Neuroradiology. 1981; 21:259-263. 
 
 
 
 
 
572 | Cucu et al - Atypical meningioma associated with multiple meningiomas 
 
 
 
 
 
 
 
21.Neuss M, Westphal M, Hansel M, et al. Clinical and 
laboratory findings in patients with multiple 
meningiomas. Br J Neurosurg. 1988; 2:249-256. 
22.Olivero WC, Lister JR, Elwood PW. The natural 
history and growth rate of asymptomatic meningiomas: a 
review of 60 patients. J Neurosurg. 1995; 83:222-224. 
23.Oshita J, Sogabe T, Maeda H, et al. A case of multiple 
meningiomas: two lesions have different 
clinicopathological features, respectively. No Shinkei 
Geka. 2007; 35: 929-934. 
24.Petrella R, Levine S, Wilmot PL, et al. Multiple 
meningiomas in a patient with constitutional ring 
chromosome 22. Am J Med Genet. 1993; 47:184-186. 
25.Salvetti DJ, Nagaraja TG, Levy C, et al. Gamma Knife 
surgery for the treatment of patients with asymptomatic 
meningiomas. J Neurosurg. 2013; 119:487-493. 
26.Samblas J, Luis Lopez Guerra J, Bustos J, et al. 
Stereotactic radiosurgery in patients with multiple 
intracranial meningiomas. J BUON. 2014; 19:250-255. 
27.Sheehy JP, Crockard HA. Multiple meningiomas: A 
long-term review. J Neurosurg. 1983; 59:1-5. 
28.Shen Y, Nunes F, Stemmer-Rachamimov A, et al. 
Genomic profiling distinguishes familial multiple and 
sporadic multiple meningiomas. BMC Med Genomics. 
2009; 2:42.  
29.Spallone A, Neroni M, Giuffre R. Multiple skull base 
meningiomas: case report. Surg Neurol. 1999; 51:274-280. 
30.Stangl AP, Wellenreuther R, Lenartz D, et al. Clonality 
of multiple meningiomas. J Neurosurg. 1997; 86:853-858. 
31.Tomita T, Kurimoto M, Yamatani K, et al. Multiple 
meningiomas consisting of fibrous meningioma and 
anaplastic meningioma, J Clin Neurosci. 2003; 10:622-
624. 
32.Touat M, Lombardi G, Farina P, et al. Successful 
treatment of multiple intracranial meningiomas with the 
antiprogesterone receptor agent mifepristone (RU486). 
Acta Neurochir (Wien). 2014; 156:1831-1835. 
33.Tsermoulas G, Turel MK, Wilcox JT, et al. 
Management of multiple meningiomas. J Neurosurg. 
2018; 128(5):1403-1409.  
34.Turgut M, Palaoğlu S, Ozcan OE, et al. Multiple 
meningiomas of the central nervous system without the 
stigmata of neurofibromatosis. Clinical and therapeutic 
study. Neurosurg Rev. 1997; 20(2):117-123. 
35.Willis J, Smith C, Ironside JW, et al. The accuracy of 
meningioma grading: a 10-year retrospective audit. 
Neuropathol Appl Neurobiol. 2005; 31: 141-149. 
36.Wong RH, Wong AK, Vick N, et al.Natural history of 
multiple meningiomas. Surg Neurol Int. 2013; 4:71. 
37.Zhu JJ, Maruyama T, Jacoby LB, et al. Clonal analysis 
of a case of multiple meningiomas using multiple 
molecular genetic approaches: Pathology case report. 
Neurosurgery. 1999; 45:409-416. 
 
